Board Institutes Inter Partes Review Of Patent Linked To Cancer Drug
ALEXANDRIA, Va. — A petitioner for inter partes review (IPR) has demonstrated that it will likely succeed in establishing that at least one challenged claim of a patent directed to a...To view the full article, register now.
Already a subscriber? Click here to view full article